Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
T14 TJ DaRenTang USD
1.010
-0.010-0.98%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Total revenue
4.47% 1.79B 3.97% 1.89B 3.42% 1.89B 4.60% 6.91B
Cost of revenue
6.03% 1.06B 3.07% 1.07B 8.32% 1.14B 3.05% 4.15B
Gross profit
2.26% 725.98M 5.18% 810.51M -3.31% 744.43M 7.04% 2.76B
Operating expense
1.20% 530.95M 1.44% 563.78M -3.35% 557.37M 8.28% 2.14B
Staff costs
-- -- -- -- -- -- 4.99% 231.13M
Selling and administrative expenses
-0.01% 632.69M 1.04% 360.42M -2.08% 521.35M 6.70% 1.65B
-Selling and marketing expense
3.95% 388.94M 6.53% 430M -1.33% 425.79M 6.76% 1.56B
-General and administrative expense
-5.75% 243.75M -48.23% -69.58M -5.27% 95.56M 5.72% 88.59M
Research and development costs
31.21% 37.09M -3.72% 35.84M -33.28% 19.33M 7.94% 161.05M
Depreciation and amortization
-- -- -- -- -- -- 0.37% 53.49M
-Depreciation
-- -- -- -- -- -- 0.37% 53.49M
Other operating expenses
3.21% 14.25M 15.86% 20.97M 6.86% 17.63M 10.00% 64.12M
Total other operating income
20.04% 3.11M -10.39% 3.42M -19.87% 949.42K -74.44% 10.9M
Operating profit
5.25% 195.02M 14.85% 246.73M -3.17% 187.06M 2.89% 613.18M
Net non-operating interest income expense
33.39% 5.21M 33.34% 15.78M 53.51% 11.82M 79.89% 44.94M
Non-operating interest income
55.36% 10.46M 36.24% 16.43M 68.13% 13.08M 79.83% 50.48M
Non-operating interest expense
-- 2.25M -- -- -- -- 44,000.67% 2.94M
Total other finance cost
2,911.36% 3M -510.64% -930.88K 1,463.75% 1.26M -15.56% 2.6M
Net investment income
526.62% 74.15M -161.71% -960.56K 256.16% 3.87M 148.47% 28.58M
Gain/Loss on financial instruments designated as cash flow hedges
Gain/Loss on derecognition of available-for-sale financial assets
Income from associates and other participating interests
-21.91% 30.74M -8.19% 56.19M -8.36% 44.42M 23.20% 185.6M
Special income /charges
68.24% -6.17M 172.95% 891.49K -311.88% -14.52M -366.08% -5.62M
Less:Impairment of capital assets
-9.43% 5.46M 92.43% 4.49M 3.54% 4.44M 351.33% 10.34M
Less:Other special charges
-- -- -- -- -- -- -63.32% -12.32M
Less:Write off
-95.36% 710.06K -304.94% -5.39M 104.33% 10.08M -20.40% 7.6M
Other non-operating income /expenses
-125.10% -849.65K -155.36% -1.61M -89.84% 156.81K 135.81% 6.13M
Income before tax
32.87% 298.1M 8.90% 317.02M -6.30% 232.8M 13.64% 872.81M
Income tax
49.65% 29.85M 16.95% 41.3M -3.46% 30.55M -2.79% 85.93M
Net income
31.23% 268.25M 7.79% 275.72M -6.72% 202.25M 15.77% 786.88M
Net income continuous operations
31.23% 268.25M 7.79% 275.72M -6.72% 202.25M 15.77% 786.88M
Noncontrolling interests
48.36% 8.07M 5.72% 6.54M -31.70% 2.64M -1.25% 17.73M
Net income attributable to the company
30.77% 260.18M 7.84% 269.18M -6.27% 199.6M 16.24% 769.14M
Preferred stock dividends
Other under preferred stock dividend
0 0 0 0
Net income attributable to common stockholders
30.77% 260.18M 7.84% 269.18M -6.27% 199.6M 16.24% 769.14M
Gross dividend payment
Basic earnings per share
30.77% 0.34 9.37% 0.35 -7.14% 0.26 16.28% 1
Diluted earnings per share
26.92% 0.33 9.37% 0.35 -7.14% 0.26 16.28% 1
Dividend per share
0 68.02% 0.5003 0 -0.42% 0.2978
Currency Unit
CNYCNYCNYCNY

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company manufactures and sells traditional Chinese medicine, western medicine, and healthcare products in the People's Republic of China. It operates in two segments namely The Chinese Medicine segment and The Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese pharmaceutical products.
CEO: --
Market: --
Watchlist